BioLineRx Ltd.
BLRXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, BioLineRx Ltd. focuses on Biotechnology services and products. BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. Valued at $12.9M, BLRX is a micro-cap name in its sector. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Market Cap
$12.9M
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
-1.06
EPS (TTM)
$0.00
EPS (Fwd)
$-2.52
ROE
-55.3%
ROA
-19.8%
Cash
$13.1M
Total Debt
$7.9M
Free CF
-$8.9M
52W Change
-26.9%
Annual Financials
Cash vs Debt
Where BLRX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BLRX finished 3.52% below its 150-day moving average ($2.84) and 5.84% below its 200-day moving average ($2.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BLRX overbought or oversold?
At the September 3, 2026 close, BLRX's RSI(14) was 50.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $13.1M in cash and $7.9M in debt, BLRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$8.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -55.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.69 suggests BLRX is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BioLineRx Ltd.'s trajectory.